In the past 10 years, with the identification of oncogenic drivers, such as epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements, the quality of life and prognosis of NSCLC patients with these driver mutations have been significantly improved when they were treated with small molecular tyrosine kinase inhibitors (TKIs) [2–4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.